Investor Relations

Listed On The Shanghai Stock Exchange In June 2001, With A Maximum Market Value Of 47.5 Billion

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Obtaining Approval Notice for Clinical Trial on Ilaprazole Tablets of Enteric-Coated Pellets

Time:2022-11-03

Ad hoc announcement pursuant to Art. 53 LR-JCARE Notice of 2022 Fourth Extraordinary General Meeting

Time:2022-10-26

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on the Plan for the Repurchase of Shares of the Company by Means of Centralized Bidding Transactions

Time:2022-10-16

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Obtaining Drug Registration Certificate for Tobramycin Inhalation Solution

Time:2022-10-14

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Obtaining Drug Registration Certificate for Acetylcysteine Solution for Inhalation

Time:2022-10-14

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on the Company's Drugs Approved for Registration in Indonesia

Time:2022-09-27

< 1...9101112 >